These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 28277842)
1. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik P; Sever J; Weizman A Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124 [TBL] [Abstract][Full Text] [Related]
4. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642 [TBL] [Abstract][Full Text] [Related]
5. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. Lewis H; Lewis J Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity. Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480 [TBL] [Abstract][Full Text] [Related]
7. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Fone KC; Nutt DJ Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631 [TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate]. Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201 [TBL] [Abstract][Full Text] [Related]
9. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Lakić A Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377 [TBL] [Abstract][Full Text] [Related]
10. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. Godfrey J J Psychopharmacol; 2009 Mar; 23(2):194-205. PubMed ID: 18515459 [TBL] [Abstract][Full Text] [Related]
11. Disordered sleep in pediatric patients with attention deficit hyperactivity disorder: an overview. Ganelin-Cohen E; Ashkenasi A Isr Med Assoc J; 2013 Nov; 15(11):705-9. PubMed ID: 24511653 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children. Kociancic T; Reed MD; Findling RL Expert Opin Drug Saf; 2004 Mar; 3(2):93-100. PubMed ID: 15006715 [TBL] [Abstract][Full Text] [Related]
13. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit]. Bricard C; Boidein F Encephale; 2001; 27(5):435-43. PubMed ID: 11760693 [TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143 [TBL] [Abstract][Full Text] [Related]
15. How high a dose of stimulant medication in adult attention deficit hyperactivity disorder? Sachdev PS; Trollor JN Aust N Z J Psychiatry; 2000 Aug; 34(4):645-50. PubMed ID: 10954396 [TBL] [Abstract][Full Text] [Related]
16. Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder. Schrantee A; Bouziane C; Bron EE; Klein S; Bottelier MA; Kooij JJS; Rombouts SARB; Reneman L Brain Imaging Behav; 2018 Apr; 12(2):402-410. PubMed ID: 28321605 [TBL] [Abstract][Full Text] [Related]
17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456 [TBL] [Abstract][Full Text] [Related]
18. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Hechtman L; Greenfield B Paediatr Drugs; 2003; 5(12):787-94. PubMed ID: 14658920 [TBL] [Abstract][Full Text] [Related]
19. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder. Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111 [TBL] [Abstract][Full Text] [Related]
20. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Baptista-Neto L; Dodds A; Rao S; Whitney J; Torres A; Gonzalez-Heydrich J Expert Opin Investig Drugs; 2008 Jan; 17(1):77-84. PubMed ID: 18095920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]